Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:HALO
- CUSIP: 40637H10
- Web: www.halozyme.com
Capitalization:- Market Cap: $1.85404 billion
- Outstanding Shares: 128,615,000
Average Prices:- 50 Day Moving Avg: $13.29
- 200 Day Moving Avg: $13.01
- 52 Week Range: $8.18 - $15.20
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -16.30
- P/E Growth: -0.24
Sales & Book Value:- Annual Revenue: $133.76 million
- Price / Sales: 13.01
- Book Value: ($0.46) per share
- Price / Book: -29.41
Profitability:- EBIDTA: ($92,040,000.00)
- Net Margins: -86.80%
- Return on Assets: -43.53%
Debt:- Debt-to-Equity Ratio: -3.15%
- Current Ratio: 3.60%
- Quick Ratio: 3.37%
Misc:- Average Volume: 1.18 million shs.
- Beta: 2.2
- Short Ratio: 17
Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its earnings results on Tuesday, May, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. The company earned $29.60 million during the quarter, compared to analyst estimates of $30.79 million. The business's revenue was down 30.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) earnings per share. View Halozyme Therapeutics' Earnings History.
Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?
7 brokerages have issued 12-month price targets for Halozyme Therapeutics' shares. Their predictions range from $6.75 to $20.00. On average, they expect Halozyme Therapeutics' share price to reach $14.63 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Intercept Pharmaceuticals (ICPT), Beigene Ltd (BGNE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), AveXis (AVXS), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR) and Array BioPharma (ARRY).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Connie L. Matsui, Chairman of the Board
- Helen I Torley, President, Chief Executive Officer, Director
- Laurie D. Stelzer, Chief Financial Officer, Senior Vice President
- Mark J. Gergen J.D., Chief Operating Officer, Senior Vice President
- Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel
- Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer
- Jean-Pierre Bizzari M.D., Independent Director
- James M. Daly, Independent Director
- Jeffrey William Henderson, Independent Director
- Kenneth J. Kelley, Independent Director
Who owns Halozyme Therapeutics stock?
Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.48%), Taylor Wealth Management Partners (0.13%), Creative Planning (0.09%), Sit Investment Associates Inc. (0.05%), Aperio Group LLC (0.02%) and Dixon Hubard Feinour & Brown Inc. VA (0.01%). View Institutional Ownership Trends for Halozyme Therapeutics.
Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?
Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?
How do I buy Halozyme Therapeutics stock?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of Halozyme Therapeutics stock can currently be purchased for approximately $13.53.
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | $14.63 (8.09% upside) |
Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/23/2017 | Barclays PLC | Reiterated Rating | Overweight | $16.00 | Low |  |
| 4/17/2017 | BMO Capital Markets | Initiated Coverage | Market Perform | $14.00 | Low | |
| 3/30/2017 | Deutsche Bank AG | Boost Price Target | Buy | $15.00 -> $17.00 | Low | |
| 1/23/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $20.00 | N/A | |
| 1/6/2017 | Citigroup Inc. | Downgrade | Buy -> Neutral | | N/A | |
| 11/8/2016 | Jefferies Group LLC | Reiterated Rating | Sell | $6.75 | N/A | |
| 9/8/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 6/6/2016 | Canaccord Genuity | Reiterated Rating | Buy | $11.00 | N/A | |
| 3/9/2016 | JMP Securities | Lower Price Target | Market Outperform | $22.00 -> $20.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Halozyme Therapeutics (NASDAQ:HALO)Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.26) | $30.79 million | $29.60 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.30) | ($0.21) | $37.94 million | $39.00 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.27) | ($0.23) | $34.43 million | $31.90 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.27) | ($0.21) | $29.94 million | $33.30 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.20) | ($0.16) | $29.65 million | $42.50 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.08) | $0.03 | $37.06 million | $52.20 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.16) | ($0.19) | $24.01 million | $20.80 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.09) | $0.02 | $24.84 million | $43.40 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.13) | ($0.12) | $19.40 million | $18.70 million | View | Listen | |
| 3/2/2015 | Q414 | ($0.07) | ($0.04) | $25.60 million | $30.38 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.14) | ($0.16) | $16.50 million | $14.60 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.18) | ($0.13) | $13.71 million | $18.40 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.14) | ($0.22) | $13.37 million | $12.00 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.17) | ($0.19) | $21.80 million | $12.50 million | View | N/A | |
| 11/8/2013 | Q313 | ($0.15) | ($0.17) | $14.62 million | $16.00 million | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.13) | ($0.13) | $11.29 million | $14.50 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.15) | ($0.17) | $7.05 million | $11.83 million | View | N/A | |
| 2/25/2013 | Q4 2012 | ($0.16) | ($0.04) | $7.32 million | $21.80 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.13) | ($0.18) | $6.09 million | $5.33 million | View | N/A | |
| 8/6/2012 | | ($0.15) | ($0.13) | | | View | N/A | |
| 5/7/2012 | | ($0.11) | $0.14 | | | View | N/A | |
| 3/9/2012 | | ($0.16) | ($0.18) | | | View | N/A | |
| 11/7/2011 | | ($0.03) | $0.05 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)2017 EPS Consensus Estimate: ($1.10)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q2 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q3 2017 | 1 | ($0.28) | ($0.28) | ($0.28) |
| Q4 2017 | 1 | ($0.28) | ($0.28) | ($0.28) |
(Data provided by Zacks Investment Research)
Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 81.37%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/20/2015 | Laurie Stelzer | CFO | Buy | 10,000 | $17.24 | $172,400.00 | |
| 6/18/2015 | Kenneth J Kelley | Director | Sell | 20,000 | $21.00 | $420,000.00 | |
| 9/16/2014 | David A Ramsay | CFO | Buy | 25,000 | $8.90 | $222,500.00 | |
| 9/16/2014 | Helen Torley | CEO | Buy | 50,000 | $8.92 | $446,000.00 | |
| 8/19/2014 | John Stuart Patton | Director | Sell | 75,000 | $9.96 | $747,000.00 | |
| 5/15/2014 | Robert Engler | Director | Sell | 126,700 | $7.56 | $957,852.00 | |
| 9/16/2013 | John Stuart Patton | Director | Sell | 75,000 | $9.13 | $684,750.00 | |
| 8/19/2013 | H. Michael Shepard | VP | Sell | 10,000 | $7.11 | $71,100.00 | |
| 8/14/2013 | Kathryn Falberg | Director | Buy | 100,000 | $6.82 | $682,000.00 | |
| 11/29/2012 | Robert Engler | Director | Buy | 15,000 | $5.57 | $83,550.00 | |
| 11/14/2012 | James P Shaffer | VP | Buy | 20,000 | $5.22 | $104,400.00 | |
| 11/13/2012 | Kathryn E Falberg | Director | Buy | 50,000 | $5.21 | $260,500.00 | |
| 8/27/2012 | Kenneth J Kelley | Director | Buy | 20,000 | $5.70 | $114,000.00 | |
| 8/13/2012 | Gregory Ian Frost | CEO | Buy | 2,000 | $5.50 | $11,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
| Source: |
|
| Date | Headline |
|---|
 | Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : July 21, 2017
finance.yahoo.com - July 21 at 3:12 PM |
 | Zacks: Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - July 16 at 10:48 AM |
 | Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy - PR Newswire (press release)
www.prnewswire.com - July 14 at 8:56 PM |
| -$0.25 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter
www.americanbankingnews.com - July 14 at 12:16 PM |
 | Halozyme Therapeutics (HALO) Announces Initiation Of Clinical ... - StreetInsider.com
www.streetinsider.com - July 13 at 3:57 PM |
| Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy
finance.yahoo.com - July 13 at 3:57 PM |
| Investor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
finance.yahoo.com - July 11 at 12:23 AM |
| Halozyme To Host Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 10 at 7:22 PM |
| Investor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
finance.yahoo.com - July 10 at 7:22 PM |
| Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'
finance.yahoo.com - July 8 at 11:17 AM |
| Martin Shkreli worker called him 'mentally unstable,' threatened to expose lies by 'scam artist'
finance.yahoo.com - July 8 at 11:17 AM |
| Former officer of Martin Shkreli hedge fund filed SEC complaint against Shkreli while at fund
finance.yahoo.com - July 8 at 11:17 AM |
 | BRIEF-Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 ... - Reuters
www.reuters.com - July 7 at 6:02 AM |
| Martin Shkreli's lawyer and 'cowboy' venture capitalist duel over value of horses and investments
finance.yahoo.com - July 7 at 6:02 AM |
| Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'
finance.yahoo.com - July 7 at 6:02 AM |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 3 at 6:32 PM |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - July 1 at 5:38 PM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June 30, 2017
finance.yahoo.com - June 30 at 7:30 PM |
| Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented ... - PR Newswire (press release)
www.prnewswire.com - June 28 at 11:54 PM |
| Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium
finance.yahoo.com - June 28 at 6:54 PM |
| Dance Biopharm Appoints Steve Thornton to Board of Directors
www.prnewswire.com - June 27 at 5:48 PM |
| Halozyme FDA Action Date, Q1 Review, Analysts Outlook and Price Targets
finance.yahoo.com - June 26 at 7:23 PM |
| ETFs with exposure to Halozyme Therapeutics, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 7:23 PM |
| Halozyme Therapeutics, Inc. (HALO) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 6:44 PM |
| FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE ... - PR Newswire (press release)
www.prnewswire.com - June 23 at 3:40 PM |
| Barclays PLC Reiterates "Overweight" Rating for Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - June 23 at 9:32 AM |
| Halozyme (HALO) Pleased by FDA Approval of Genentech's RITUXAN HYCELA
www.streetinsider.com - June 23 at 2:58 AM |
| FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology
finance.yahoo.com - June 23 at 2:58 AM |
| $33.11 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - June 22 at 12:42 PM |
| -$0.25 EPS Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - June 20 at 8:07 AM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : June 19, 2017
finance.yahoo.com - June 19 at 12:40 PM |
| Halozyme Therapeutics, Inc. (HALO) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - June 16 at 10:34 PM |
 | Notable Friday Option Activity: FINL, X, HALO
www.nasdaq.com - June 16 at 6:24 PM |
| ETFs with exposure to Halozyme Therapeutics, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 6:24 PM |
| Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:50 AM |
| Halozyme Therapeutics, Inc. (HALO) Short Interest Update
www.americanbankingnews.com - June 12 at 7:14 AM |
| Halozyme Therapeutics, Inc. (HALO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 6 at 6:23 PM |
 | Why Halozyme Therapeutics Inc. Sank 16.5% in May - Motley Fool
www.fool.com - June 6 at 6:03 PM |
| Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO - PR Newswire (press release)
www.prnewswire.com - June 5 at 3:34 PM |
| Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
finance.yahoo.com - June 4 at 5:45 PM |
| Halozyme Therapeutics, Inc. (HALO) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 1:04 PM |
| Zacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - May 26 at 11:57 AM |
| Zacks: Brokerages Expect Halozyme Therapeutics, Inc. (HALO) to Post -$0.25 EPS
www.americanbankingnews.com - May 25 at 12:20 AM |
| Halozyme Therapeutics Announces Completion Of Public Offering And Full ...
www.prnewswire.com - May 24 at 5:28 PM |
| Halozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
finance.yahoo.com - May 24 at 5:28 PM |
 | Halozyme: PEGPH20 Clinical Development Progress Does Not Yet Translate To Value
seekingalpha.com - May 23 at 5:12 PM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May 22, 2017
finance.yahoo.com - May 22 at 11:09 AM |
| Halozyme Therapeutics (HALO) Prices 10M Share Offering at $12.50/Sh
www.streetinsider.com - May 20 at 10:31 PM |
| Mid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge - Nasdaq
www.nasdaq.com - May 19 at 10:24 PM |
| Halozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10% - Motley Fool
www.fool.com - May 19 at 10:24 PM |
Halozyme Therapeutics (HALO) Chart for Saturday, July, 22, 2017
